AUC resulting from administration of an intraduodenal release dosage form having an equivalent amount of said Compound (I) and/or said pharmaceutically acceptable salt thereof provided that not more than about 10% of the AUC resulting from administration of said solid oral dosage form is contributed within about 1.5 to about 2 hours after dosing when the solid oral dosage form is administered to a mammal in the fasted state. .

In a fifth aspect, provided is a solid oral dosage form comprising:

(i) Compound (I) and/or a pharmaceutically acceptable salt thereof;

(ii) an enteric coating which releases Compound (I) and/or said pharmaceutically salt thereof in one or more mammalian intestinal sites chosen from the duodenum, jejunum, ileum, and colon; and

(iii) a pharmaceutically acceptable excipient.

In a sixth apect, provided is the use of a therapeutically effective amount of Compound (I) and/or a pharmaceutically acceptable salt thereof in a solid oral dosage form of any of first, second, third, fourth, or fifth aspects (or embodiments thereof disclosed herein) in the manufacture of a medicament for inhibiting BTK in an mammal in need thereof.

In a seventh aspect provided is the use of a therapeutically effective amount of Compound (I) and/or a pharmaceutically acceptable salt thereof in a solid oral dosage form of any of first, second, third, fourth, or fifth aspects (or embodiments thereof disclosed herein) in the manufacture of a medicament for treating a disease mediated by BTK in amammal in need thereof.

In one embodiment of seventh aspect, the mammal in need of such disease treatment is suffering from an autoimmune disease, e.g., thrombotic thrombocytopenic purpura, Polyarteritis Nodosa, Cutaneous lupus, cutaneous form of systemic sclerosis (CREST), systemic sclerosis, mixed connective tissue disease, cryoglobulinemia, primary biliary sclerosis, sclerosing cholangitis, AI urticarial, IgA nephropathy, inflammatory bowel disease (such as ulcerative colitis), lupus including lupus nephritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Granulomatosis with Polyangiitis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, Sjogren's syndrome, Sjogren's dry eye, non-Sjogren's dry eye disease, multiple sclerosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease,

opsoclonus-myoclonus syndrome, ankylosing spondylitisis, multiple sclerosis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, coeliac disease,

disintegrants, antioxidants, antifoaming agents, fillers, flavors, colors, lubricants, sorbents, preservatives, plasticizers, and sweeteners.

53. The solid oral dosage form of any of claims 11 to 52 wherein the average systemic bioavailability of Compound (I) as measured by plasma AUC resulting from administration of said dosage form is from about 200% to 4000% of the average systemic bioavailability, as measured by plasma AUC, resulting from administration of an immediate release dosage form having an equivalent amount of Compound (I) and/or said pharmaceutically acceptable salt thereof.

54. The solid oral dosage form of any of claims 11 to 52 wherein the average systemic bioavailability of Compound (I) as measured by plasma AUC resulting from administration of said pharmaceutical dosage form is from about 125% to about 2000% of the average systemic bioavailability as measured by plasma AUC resulting from administration of an intraduodenal release dosage form having an equivalent amount of Compound (I) and/or said pharmaceutically acceptable salt thereof.

55. Use of a therapeutically effective amount of Compound (I) and/or a pharmaceutically acceptable salt thereof in a solid oral dosage form of any of Claims 1-54 in the manufacture of a medicament for inhibiting BTK in an mammal in need thereof.

56. Use of a therapeutically effective amount of Compound (I) and/or a pharmaceutically acceptable salt thereof in a solid oral dosage form of any of Claims 1-54 in the manufacture of a medicament for treating a disease mediated by BTK in an mammal in need thereof.

57. The use of claim 56 wherein the disease is chosen from an autoimmune disease, cancer, and an inflammatory disease.